Jonathon B. Cohen, MD, MS | Winship ...

Dr. Jonathon Cohen, MD

Claim this profile

Emory University Hospital/Winship Cancer Institute

Studies Mantle Cell Lymphoma
Studies Diffuse Large B-Cell Lymphoma
8 reported clinical trials
13 drugs studied

Area of expertise

1Mantle Cell Lymphoma
Jonathon Cohen, MD has run 4 trials for Mantle Cell Lymphoma. Some of their research focus areas include:
Stage I
t(11;14)
t(11;14) positive
2Diffuse Large B-Cell Lymphoma
Jonathon Cohen, MD has run 3 trials for Diffuse Large B-Cell Lymphoma. Some of their research focus areas include:
MYC positive
BCL2 positive
BCL6 positive

Affiliated Hospitals

Image of trial facility.
Emory University Hospital/Winship Cancer Institute
Image of trial facility.
Emory Saint Joseph's Hospital

Clinical Trials Jonathon Cohen, MD is currently running

Image of trial facility.

Long-Term Follow-Up

for CAR-T Therapy Safety

Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector persistence.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Zanubrutinib

for Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting2 awards Phase 310 criteria

More about Jonathon Cohen, MD

Clinical Trial Related10 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Jonathon Cohen, MD has experience with
  • Ibrutinib
  • CAR-T
  • CTL019
  • Cyclophosphamide
  • Oral Azacitidine
  • Rituximab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jonathon Cohen, MD specialize in?
Is Jonathon Cohen, MD currently recruiting for clinical trials?
Are there any treatments that Jonathon Cohen, MD has studied deeply?
What is the best way to schedule an appointment with Jonathon Cohen, MD?
What is the office address of Jonathon Cohen, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security